Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors

被引：0
|
作者：
Zhang, Yan
Zhou, Lin
Gong, Youling
Huang, Meijuan
Tang, Min
Liu, Yongmei
Yu, Min
Xiu, Weigang
Liang, Xinjun
Liu, Xinyu
Fu, Xin-Yuan
Lu, You
机构：
[1] Sichuan Univ, Dept Thorac Oncol, Canc Ctr, West China Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Thorac Oncol Ward, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[4] West China Hosp, Sch Med, Dept Thorac Oncol, Canc Ctr, Chengdu, Peoples R China
[5] Hubei Canc Hosp, Dept Med Oncol, Wuhan, Peoples R China
[6] GenEros Biopharma Ltd, Clin Dev Dept, Hangzhou, Peoples R China
[7] Sichuan Univ, Inst Human Dis & Immunotherapy, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9112
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation
    Waizenegger, Irene C.
    Lu, Hengyu
    Thamer, Claus
    Savarese, Fabio
    Gerlach, Daniel
    Rudolph, Dorothea
    Vellano, Christopher P.
    Marotti, Marcelo
    Heymach, John
    Kopetz, Scott
    Heffernan, Timothy P.
    Marszalek, Joseph R.
    Petronczki, Mark P.
    Hofmann, Marco H.
    Kraut, Norbert
    CANCER RESEARCH, 2022, 82 (12)
  • [32] A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors
    Papadopoulos, Kyriakos P.
    Sharma, Manish
    Dummer, Reinhard
    Imedio, Esteban Rodrigo
    Yge, Marie-Laurence
    Micallef, Sandrine
    Bellon, Anne
    Stathis, Anastasios
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors
    Juric, Dejan
    Barve, Minal
    Vaishampayan, Ulka
    Roda, Desamparados
    Calvo, Aitana
    Janez, Noelia Martinez
    Trigo, Jose
    Greystoke, Alastair
    Harvey, R. Donald
    Olszanski, Anthony J.
    Opyrchal, Mateusz
    Spira, Alexander
    Thistlethwaite, Fiona
    Jimenez, Begona
    Sappal, Jessica Huck
    Kannan, Karuppiah
    Riley, Jason
    Li, Cheryl
    Li, Cong
    Gregory, Richard C.
    Miao, Harry
    Wang, Shining
    CANCER MEDICINE, 2024, 13 (05):
  • [34] A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)
    Hong, David S.
    Yaeger, Rona
    Kuboki, Yasutoshi
    Masuishi, Toshiki
    Barve, Minal A.
    Falchook, Gerald Steven
    Govindan, Ramaswamy
    Sohal, Davendra
    Kasi, Pashtoon Murtaza
    Burns, Timothy F.
    Langer, Corey J.
    Puri, Sonam
    Chan, Emily
    Jafarinasabian, Pegah
    Ngarmchamnanrith, Gataree
    Rehn, Marko
    Tran, Qui
    Gandara, David R.
    Strickler, John H.
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [35] A phase 1 study of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors: Updated safety, efficacy, and pharmacokinetics (PK) results
    Prenen, Hans
    Daniel, Jeannie
    Ebiana, Victoria
    Howe, Jason
    Gong, Xiaohua
    Spitz, Susan
    Italiano, Antoine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors.
    Boni, Valentina
    Garralda, Elena
    Colombo, Ilaria
    Homicsko, Krisztian
    Brana, Irene
    Gruber, Dorothea
    Fluckiger-Mangual, Stefanie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [38] Phase 1 study of ipatasertib (AKT inhibitor) for investigating safety, tolerability, pharmacokinetics (PK), efficacy, and biomarkers in Japanese patients (pts) with solid tumors including castration-resistant prostate cancer (CRPC)
    Takahashi, S.
    Fujiwara, Y.
    Matsubara, N.
    Tomomatsu, J.
    Iwasa, S.
    Yamasaki, A.
    Endo, C.
    Yokoyama, S.
    Doi, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    Dy, Grace K.
    Zhao, Yujie
    Ma, Wen Wee
    Opyrchal, Mateusz
    Bakhribah, Hatoon
    Jacob, Sandra M.
    O'Hara, Corrie
    Dozier, Askia
    Cmiljanovic, Natasa
    Todaro, Barbara
    Brady, William E.
    Schmitz, Debora
    Dimitrijevic, Sasa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Inhibition of autophagy: Phase I safety, tolerability, and pharmacokinetics (PK) of hydroxychloroquine (H) in combination with vorinostat (V) in patients with advanced solid tumors
    Mahalingam, Devalingam
    Mita, Monica M.
    Sarantopoulos, John
    Wood, Leslie
    Mita, Alain C.
    Curiel, Tyler J.
    Argiris, Athanassios
    Nawrocki, Steffan T.
    Carew, Jennifer S.
    Giles, Francis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345